An α7 nAChR agonist is also used as a cognitive enhancer in patients with schizophrenia (Freedman, 2013) and Alzheimer’s disease (Hilt et al., 2009). This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.